SOLARA

Solara Active Pharma Sciences Ltd emerged as a pure-play active pharmaceutical ingredients (API) company following its formation through the demerger of the API business from Strides Shasun Ltd (now Stride Pharma Sciences) and subsequent acquisition of the human API business from Sequent Scientific Ltd. The company is engaged in manufacturing, production, processing, formulating, sale, import, export, merchandising, distribution, and trading of APIs, alongside providing contract research and manufacturing services (CRAMS). It operates six manufacturing facilities and one research and development center, supporting a portfolio exceeding 60 commercial API products. Solara serves customers across more than 70 countries and focuses on high-value commercial APIs and profitable, high-margin business segments. Notably, it has undertaken recovery and reset activities following a fire incident at its Puducherry facility during the fiscal year 2024-25.